Neonc Technologies President Buys 10,000 Shares

Insider buying signals confidence in the company's future

Apr. 10, 2026 at 10:18am

Got story updates? Submit your updates here. ›

An extreme close-up of heavy, industrial banking equipment and machinery, conveying a sense of institutional financial power and security without using literal currency or charts.An insider's view of the intricate financial infrastructure powering Neonc Technologies' growth and innovation.Los Angeles Today

Neonc Technologies Holdings, Inc. (NASDAQ:NTHI) President Amir Heshmatpour purchased 10,000 shares of the company's stock on April 8th, 2026 at an average price of $5.61 per share. This transaction increased Heshmatpour's direct ownership stake in the company to 3,027,000 shares, valued at approximately $16.98 million.

Why it matters

Insider buying activity is often viewed as a positive signal, as company insiders are generally well-informed about their business's prospects and future performance. Heshmatpour's substantial purchase of Neonc Technologies stock suggests he is confident in the company's long-term growth potential.

The details

Heshmatpour's purchase of 10,000 shares represents a 0.33% increase in his direct ownership of Neonc Technologies. The company is a developer of novel molecular technologies for treating central nervous system diseases, with lead products NEO100 and NEO212 in clinical and preclinical testing, respectively.

  • The stock purchase was made on Wednesday, April 8th, 2026.

The players

Amir Heshmatpour

President of Neonc Technologies Holdings, Inc.

Neonc Technologies Holdings, Inc.

A developer of novel molecular technologies for treating central nervous system diseases.

Got photos? Submit your photos here. ›

What’s next

Investors will likely continue to monitor Neonc Technologies' progress with its lead drug candidates and any further insider buying or selling activity.

The takeaway

Heshmatpour's substantial purchase of Neonc Technologies stock suggests he sees significant upside potential in the company's pipeline of central nervous system treatments. This insider buying activity could signal growing confidence in the firm's future prospects.